Duloxetine
Product Images NDC 50090-3205

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-3205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride illustrating its molecular framework, including a thiophene ring, a naphthalene moiety, and a methylated amine hydrochloride group.*

FDA Label Image

Figure 1 (Duloxetine 02)

A Kaplan-Meier curve comparing the proportion of patients with relapse over time (days) between placebo and duloxetine delayed-release capsules. The graph shows time from randomization to relapse on the x-axis and proportion of patients with relapse on the y-axis, illustrating lower relapse rates for duloxetine delayed-release capsules across approximately 200 days of follow-up.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve chart comparing relapse rates over time between patients treated with duloxetine delayed-release capsules and placebo. The x-axis represents time from randomization to relapse in days, while the y-axis shows the proportion of patients with relapse. The curve for duloxetine delayed-release capsules shows a consistently lower proportion of relapse compared to placebo across the study period.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved against percent improvement in pain from baseline. The graph compares four groups labeled DUL 60 mg BID, DUL 60 mg QD, DUL 20 mg QD, and Placebo, showing trends of patient improvement across varying pain improvement percentages.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing percent improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis. It compares three groups: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo, illustrating the proportion of patients achieving various levels of pain improvement.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60mg Twice Daily, Duloxetine 60mg Once Daily, and Placebo, showing the trend of patient improvement across different pain improvement thresholds.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line chart showing the percentage of patients improved across varying levels of percent improvement in pain from baseline. The chart compares four groups labeled as Duloxetine 120mg once daily, Duloxetine 60mg once daily, Duloxetine 20mg once daily, and placebo. The vertical axis represents the percentage of patients improved, while the horizontal axis shows percent improvement in pain from 0 to 100.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line chart comparing the percentage of patients improved in pain by percent improvement from baseline for Duloxetine Delayed-Release (DUL 60/120 mg once daily) versus placebo. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Two lines illustrate treatment effects across various improvement thresholds.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF). It shows two series: placebo and Duloxetine Delayed-Release 60 mg once daily, with Duloxetine showing a generally higher percentage of patients improved across the pain improvement spectrum.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF). It shows two data series: placebo and Duloxetine Delayed-Release (60/120 mg once daily), illustrating patient response rates across varying levels of pain improvement.*

FDA Label Image

Label Image (Lbl500903205)

Label for Duloxetine Delayed-Release 30 mg capsules by A-S Medication Solutions, product NDC 50090-3205. Each capsule contains 30 mg duloxetine as delayed-release capsules. The label includes storage instructions to store at 77 degrees Fahrenheit and a quantity of 30 capsules. Additional packaging and manufacturer information is also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.